Multimodality treatment in recurrent/metastatic squamous cell carcinoma of head and neck: current therapy, challenges, and future perspectives

被引：7

作者：

Pannunzio, Sergio ^{[1
]}

Di Bello, Armando ^{[1
]}

Occhipinti, Denis ^{[1
]}

Scala, Alessandro ^{[1
]}

Messina, Gloria ^{[1
]}

Valente, Giustina ^{[1
]}

Quirino, Michela ^{[1
]}

Di Salvatore, Mariantonietta ^{[1
]}

Tortora, Giampaolo ^{[1
,2
]}

Cassano, Alessandra ^{[1
,2
]}

机构：

[1] Ist Ricovero & Cura Carattere Sci IRCCS, Fdn Policlin Univ Agostino Gemelli, Oncol Med, Rome, Italy

[2] IRCCS, Fdn Policlin Univ Agostino Gemelli, Comprehens Canc Ctr, Rome, Italy

来源：

FRONTIERS IN ONCOLOGY | 2024年 / 13卷

关键词：

head and neck; squamous cell carcinoma; recurrent; metastatic; multimodality treatment; surgery; radiation therapy; chemotherapy; QUALITY-OF-LIFE; AND/OR METASTATIC HEAD; PHASE-II TRIAL; SALVAGE SURGERY; OPEN-LABEL; 1ST-LINE TREATMENT; PALLIATIVE RADIOTHERAPY; INVESTIGATORS CHOICE; WEEKLY PACLITAXEL; CANCER PATIENTS;

D O I：

10.3389/fonc.2023.1288695

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Squamous cell carcinoma of the head and neck is a complex group of diseases that presents a challenge to the clinician. The prognosis in the recurrent/metastatic disease is particularly dismal, with a median survival of approximately 12 months. Recently, the personalized and multimodal approach has increased prognosis by integrating locoregional strategies (salvage surgery and stereotactic radiotherapy) and systemic treatments (chemotherapy, immunotherapy, and target therapy). Malnutrition is a significant clinical problem that interferes with dose intensity, and thus, feeding supplementation is critical not only to increase the quality of life but also to improve overall survival. With this review, we want to emphasize the importance of the multidisciplinary approach, quality of life, and nutritional supportive care and to integrate the latest updates of predictive biomarkers for immunotherapy and future therapeutic strategies.

引用

页数：17

共 137 条

[1] THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].

AARONSON, NK ;

AHMEDZAI, S ;

BERGMAN, B ;

BULLINGER, M ;

CULL, A ;

DUEZ, NJ ;

FILIBERTI, A ;

FLECHTNER, H ;

FLEISHMAN, SB ;

DEHAES, JCJM ;

KAASA, S ;

KLEE, M ;

OSOBA, D ;

RAZAVI, D ;

ROFE, PB ;

SCHRAUB, S ;

SNEEUW, K ;

SULLIVAN, M ;

TAKEDA, F .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376

[2] Immunotherapy orchestrates radiotherapy in composing abscopal effects: A strategic review in metastatic head and neck cancer [J].

Akbor, Mohammady ;

Hung, Kai-Feng ;

Yang, Yi-Ping ;

Chou, Shih-Jie ;

Tsai, Ping-Hsing ;

Chien, Chian-Shiu ;

Lin, Liang-Ting .

JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2020, 83 (02) :113-116

[3] Nutritional Considerations for Head and Neck Cancer Patients: A Review of the Literature [J].

Alshadwi, Ahmad ;

Nadershah, Mohammed ;

Carlson, Eric R. ;

Young, Lorrie S. ;

Burke, Peter A. ;

Daley, Brian J. .

JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2013, 71 (11) :1853-1860

[4] Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines [J].

Arends, J. ;

Strasser, F. ;

Gonella, S. ;

Solheim, T. S. ;

Madeddu, C. ;

Ravasco, P. ;

Buonaccorso, L. ;

de van der Schueren, M. A. E. ;

Baldwin, C. ;

Chasen, M. ;

Ripamonti, C., I .

ESMO OPEN, 2021, 6 (03)

[5]

Bauman JE, 2023, J CLIN ONCOL, V41, P3851, DOI 10.1200/JCO.22.01994

[6] Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade [J].

Benci, Joseph L. ;

Xu, Bihui ;

Qiu, Yu ;

Wu, Tony J. ;

Dada, Hannah ;

Twyman-Saint Victor, Christina ;

Cucolo, Lisa ;

Lee, David S. M. ;

Pauken, Kristen E. ;

Huang, Alexander C. ;

Gangadhar, Tara C. ;

Amaravadi, Ravi K. ;

Schuchter, Lynn M. ;

Feldman, Michael D. ;

Ishwaran, Hemant ;

Vonderheide, Robert H. ;

Maity, Amit ;

Wherry, E. John ;

Minn, Andy J. .

CELL, 2016, 167 (06) :1540-+

[7] A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients [J].

Bjordal, K ;

de Graeff, A ;

Fayers, PM ;

Hammerlid, E ;

van Pottelsberghe, C ;

Curran, D ;

Ahlner-Elmqvist, M ;

Maher, EJ ;

Meyza, JW ;

Brédart, A ;

Söderholm, AL ;

Arraras, JJ ;

Feine, JS ;

Abendstein, H ;

Morton, RP ;

Pignon, T ;

Huguenin, P ;

Bottomly, A ;

Kaasa, S .

EUROPEAN JOURNAL OF CANCER, 2000, 36 (14) :1796-1807

[8] Differential expression of PDL-1 between primary and recurrent/metastatic head and neck squamous cell carcinoma: Analysis of concordance and factors impacting on variations [J].

Bossi, P. ;

Mattavelli, D. ;

Battocchio, S. ;

Martini, M. ;

Calza, S. ;

Lorini, L. ;

Baldassarra, D. ;

Zigliani, G. ;

Piazza, C. ;

Morbini, P. .

ANNALS OF ONCOLOGY, 2022, 33 (07) :S857-S857

[9] A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck [J].

Bossi, P. ;

Miceli, R. ;

Locati, L. D. ;

Ferrari, D. ;

Vecchio, S. ;

Moretti, G. ;

Denaro, N. ;

Caponigro, F. ;

Airoldi, M. ;

Moro, C. ;

Vaccher, E. ;

Sponghini, A. ;

Caldara, A. ;

Rinaldi, G. ;

Ferrau, F. ;

Nole, F. ;

Lo Vullo, S. ;

Tettamanzi, F. ;

Hollander, L. ;

Licitra, L. .

ANNALS OF ONCOLOGY, 2017, 28 (11) :2820-2826

[10] Rapid-Onset Opioids for Management of Breakthrough Cancer Pain: Considerations for Daily Practice [J].

Bossi, Paolo ;

Escobar, Yolanda ;

Pea, Federico .

FRONTIERS IN PAIN RESEARCH, 2022, 3

← 1 2 3 4 5 6 7 8 9 10 →